Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions

Shou Ching Tang

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Anthracyclines were standard chemotherapy agents in the adjuvant treatment of early breast cancer. Taxanes are newer tubulin-targeting agents that have little cross-resistance and limited overlapping toxicities with anthracyclines. In the past decade, large number of randomized phase-III clinical trials has been conducted worldwide to determine if the addition of taxanes to anthracyclines would improve the disease-free or overall survival of patients with early breast cancer. Many of these first-generation taxane trials are now mature with available survival data. Pooled analyses from these trials consistently demonstrated survival advantage when taxanes were added to anthracyclines or nonanthracycline regimen. The second-generation taxane trials are focusing on how to optimally combine taxanes with the anthracyclines, sequentially, or concurrently, dosing and frequency of administration, duration of therapy and measures to reduce the taxane toxicity. The future direction of clinical research on taxanes or third-generation taxane trials involves identification of predictive markers for response to taxanes, application of novel taxanes and combination of taxanes to other biological agents in order to offer taxanes to selected patients with early breast cancer to increase the efficacy and minimize the toxicity. While many of the second-generation taxane trials are still ongoing, the choice of specific taxane regimen should be based on evidence from the published clinical trials and tailoring to the particular needs of individual patient.

Original languageEnglish (US)
Pages (from-to)489-495
Number of pages7
JournalCancer Investigation
Volume27
Issue number5
DOIs
StatePublished - Jun 1 2009

Fingerprint

Taxoids
Breast Neoplasms
Anthracyclines
Therapeutics
Survival
Phase III Clinical Trials
Biological Factors
Tubulin
taxane
Randomized Controlled Trials
Clinical Trials
Drug Therapy

Keywords

  • Anthracyclines
  • Clinical trials
  • Disease-free and overall survival
  • Docetaxel
  • Dosage
  • Early breast cancer
  • Meta-analysis
  • Paclitaxel
  • Scheduling and safety
  • Sequencing
  • Taxanes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions. / Tang, Shou Ching.

In: Cancer Investigation, Vol. 27, No. 5, 01.06.2009, p. 489-495.

Research output: Contribution to journalReview article

@article{a8f8b79afcda47e8a3380c31f496212d,
title = "Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions",
abstract = "Anthracyclines were standard chemotherapy agents in the adjuvant treatment of early breast cancer. Taxanes are newer tubulin-targeting agents that have little cross-resistance and limited overlapping toxicities with anthracyclines. In the past decade, large number of randomized phase-III clinical trials has been conducted worldwide to determine if the addition of taxanes to anthracyclines would improve the disease-free or overall survival of patients with early breast cancer. Many of these first-generation taxane trials are now mature with available survival data. Pooled analyses from these trials consistently demonstrated survival advantage when taxanes were added to anthracyclines or nonanthracycline regimen. The second-generation taxane trials are focusing on how to optimally combine taxanes with the anthracyclines, sequentially, or concurrently, dosing and frequency of administration, duration of therapy and measures to reduce the taxane toxicity. The future direction of clinical research on taxanes or third-generation taxane trials involves identification of predictive markers for response to taxanes, application of novel taxanes and combination of taxanes to other biological agents in order to offer taxanes to selected patients with early breast cancer to increase the efficacy and minimize the toxicity. While many of the second-generation taxane trials are still ongoing, the choice of specific taxane regimen should be based on evidence from the published clinical trials and tailoring to the particular needs of individual patient.",
keywords = "Anthracyclines, Clinical trials, Disease-free and overall survival, Docetaxel, Dosage, Early breast cancer, Meta-analysis, Paclitaxel, Scheduling and safety, Sequencing, Taxanes",
author = "Tang, {Shou Ching}",
year = "2009",
month = "6",
day = "1",
doi = "10.1080/07357900802427943",
language = "English (US)",
volume = "27",
pages = "489--495",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions

AU - Tang, Shou Ching

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Anthracyclines were standard chemotherapy agents in the adjuvant treatment of early breast cancer. Taxanes are newer tubulin-targeting agents that have little cross-resistance and limited overlapping toxicities with anthracyclines. In the past decade, large number of randomized phase-III clinical trials has been conducted worldwide to determine if the addition of taxanes to anthracyclines would improve the disease-free or overall survival of patients with early breast cancer. Many of these first-generation taxane trials are now mature with available survival data. Pooled analyses from these trials consistently demonstrated survival advantage when taxanes were added to anthracyclines or nonanthracycline regimen. The second-generation taxane trials are focusing on how to optimally combine taxanes with the anthracyclines, sequentially, or concurrently, dosing and frequency of administration, duration of therapy and measures to reduce the taxane toxicity. The future direction of clinical research on taxanes or third-generation taxane trials involves identification of predictive markers for response to taxanes, application of novel taxanes and combination of taxanes to other biological agents in order to offer taxanes to selected patients with early breast cancer to increase the efficacy and minimize the toxicity. While many of the second-generation taxane trials are still ongoing, the choice of specific taxane regimen should be based on evidence from the published clinical trials and tailoring to the particular needs of individual patient.

AB - Anthracyclines were standard chemotherapy agents in the adjuvant treatment of early breast cancer. Taxanes are newer tubulin-targeting agents that have little cross-resistance and limited overlapping toxicities with anthracyclines. In the past decade, large number of randomized phase-III clinical trials has been conducted worldwide to determine if the addition of taxanes to anthracyclines would improve the disease-free or overall survival of patients with early breast cancer. Many of these first-generation taxane trials are now mature with available survival data. Pooled analyses from these trials consistently demonstrated survival advantage when taxanes were added to anthracyclines or nonanthracycline regimen. The second-generation taxane trials are focusing on how to optimally combine taxanes with the anthracyclines, sequentially, or concurrently, dosing and frequency of administration, duration of therapy and measures to reduce the taxane toxicity. The future direction of clinical research on taxanes or third-generation taxane trials involves identification of predictive markers for response to taxanes, application of novel taxanes and combination of taxanes to other biological agents in order to offer taxanes to selected patients with early breast cancer to increase the efficacy and minimize the toxicity. While many of the second-generation taxane trials are still ongoing, the choice of specific taxane regimen should be based on evidence from the published clinical trials and tailoring to the particular needs of individual patient.

KW - Anthracyclines

KW - Clinical trials

KW - Disease-free and overall survival

KW - Docetaxel

KW - Dosage

KW - Early breast cancer

KW - Meta-analysis

KW - Paclitaxel

KW - Scheduling and safety

KW - Sequencing

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=67449105933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449105933&partnerID=8YFLogxK

U2 - 10.1080/07357900802427943

DO - 10.1080/07357900802427943

M3 - Review article

C2 - 19479486

AN - SCOPUS:67449105933

VL - 27

SP - 489

EP - 495

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 5

ER -